Objective To observe the anti-inflammatory effects of rhamnocitrin in Oxytropis falcata Bunge;To provide experimental evidence for searching the anti-inflammatory active component of Oxytropis falcata Bunge. Methods Kunming mice or Wistar rats were randomly divided into model group, naproxen group and rhamnocitrin high-, medium-, low-dose groups, and corresponding medicines were administered by gavage for 7 days. Animal inflammatory models were established respectively by the mice ear swelling induced by dimethylbenzene, the mice abdominal capillary permeability induced by acetic acid, the rat paw edema created by injection of albumen and the rat granuloma induced by cotton pellet wool. The effects of rhamnocitrin on acute and chronic inflammatory animal models were observed. Results Different doses of rhamnocitrin groups could reduce the animal ear swelling, abdominal capillary permeability, paw edema and granuloma. Compared with the model group, there were obvious differences in rhamnocitrin groups (P<0.05). High dose rhamnocitrin group and naproxen group showed relatively strong inhibition effects on swelling, with statistical significance (P<0.05). Conclusion Rhamnocitrin has anti-inflammatory effects and is an important biological component of Oxytropis falcata Bunge.

Objective To identify Oxytropis falcate Bunge from its adulterants;To secure the quality and clinical efficacy of Oxytropis falcate Bunge. Methods Genomic DNA was extracted. ITS2 fragment of nuclear gene was amplified and sequenced. The homology of the sequences was analyzed, and the related data were analyzed by software MEGA. The NJ (neighbor-joining) tree was constructed based on ITS2 sequence. Results The intraspecific genetic distance of Oxytropis falcate Bunge (K2P distance) was 0, and the interspecific genetic distance (K2P distance) between Oxytropis falcate Bunge and its adulterants ranged among 0.068-0.084. The constructed NJ tree showed that ITS2 could identify Oxytropis falcate Bunge from its adulterants correctly. Conclusion ITS2 barcode can be used to identify Oxytropis falcate Bunge from its adulterants effectively, and this study provides important molecular evidence for the identification of Oxytropis falcate Bunge and safety in its clinical use.

Objective To study the pharmacopoeia standards of Hedysari Radix;To optimize the quality standards of Hedysari Radix medicinal materials.Methods Quality standards of eight batches of Hedysari Radix medicinal materials were studied from the aspects of properties, TLC identification, HPLC determination, the content of water and total ash, alcohol soluble extract, etc. Results The property description was different from the previous literature. The effects of TLC identification using ethyl acetate-chloroform-water (4:9:1) system is better than the standards in 2010 edition of Chinese Pharmacopoeia. With formononetin as reference, the HPLC characteristic spectrum of Hedysari Radix was established.Conclusion The TLC identification method is simple, accurate and reliable.

A model of myelosuppression with thrombocytopenia was produced in monkey by i.v. administration of carboplatin to the evaluate effects of rhIL-11 treatment in monkeys. Following myelosuppression, rhIL-11 was subcutaneously injected for 19 consecutive days at the dose of 50 or 100 micro g/kg. In myelosuppressed monkeys treated with rhIL-11, peripheral blood platelet started to drop at the day 8 after the administration of carboplatin, and reaching the nadir between the day 12 - 14, the decrease in blood platelet was less severe compared with untreated monkeys; peripheral blood platelet began to recovery on day 11 - 13 (D14 - D16) after rhIL-11 treatment, and reached or surpassed the baseline value before carboplatin administration after 13 - 15 days rhIL-11 treatment. Blood platelet counts remained high level after discontinuation of rhIL-11 administration and returned to baseline after 4 days. The results demonstrated that rhIL-11 has a significant thrombopoietic activity, it can reduce the severity of thrombocytopenia as well as shorten the duration of thrombocytopenia caused by myeloablastive agents, and is likely to become an effective agent against thrombocytopenia induced by chemotherapy.

Hematological effects of rhIL-11 on normal and myelosuppressed male BALB/c mice were observed. Mice were subcutaneously injected with rhIL-11 for 7 consecutive days, at the dose of 200 or 400 micro g/kg per day, peripheral blood platelet counts were moderately elevated on 5 days after administration and returned to base level within 4 days after discontinuation of injection. In myelosuppressed mice, treatment with rhIL-11 significantly ameliorated the degree of thrombocytopenia, the recovery of thrombocytopenia was also significantly accelerated at the dose range of 100 - 400 micro g/kg per day, and blood platelet counts reached pre-irradiated level after 13 - 15 days of treatment. The magnitudes of platelet count elevation were similar among groups of 100, 200 and 400 micro g/kg per day, although recovery appeared earlier in group of 400 micro g/kg per day. Significant increases in CFU-Meg were observed both in normal and myelosuppressed mice. Our results suggest that rhIL-11 promotes the increase of peripheral blood platelets both in normal and myelosuppressed mice, and can be used as a potential therapeutic agent for thrombocytopenia induced by chemotherapy.